Over the past two years, the world has seen major developments in Alzheimer’s disease treatment with the release of two new medications: Lecanamab, marketed as Leqembi, and Donanemab, marketed as Kisunla. These two treatments are the first of their kind to reduce the physical signs of Alzheimer’s disease in the brain and potentially slow down the progression of cognitive decline.

In the premiere episode of season 2 of the Age of Aging, we explore these new anti-amyloid therapies, what they are, and how they may change the lives of patients and caregivers.

We begin with the personal story of a couple who have participated in the Donanemab clinical trials over the past three years, sharing their firsthand experiences with the medication. Project Manager of this trial at the Penn Memory Center, Melissa Kelley, provides insights into the journey of these participants. Additionally, Dr. Sanjeev Vaishnavi offers an expert breakdown of anti-amyloid therapies, explaining what they are, how they work, and what they might mean for the future of Alzheimer’s disease treatment.

Resources

• More resources on Lecanamab (Leqembi)
• Learn more about disease modifying therapies for Alzheimer’s disease
• Check out studies currently enrolling at the Penn Memory Center.

Special thanks to Dan and Susan Henderson, Melissa Kelley, and Sanjeev Vaishnavi MD, PhD, for contributing to this episode.

The Age of Aging is a Penn Memory Center production hosted by Editorial Director Terrence Casey and Producer Jake Johnson, in partnership with the Penn FTD Center, the Penn Institute on Aging, and UPenn’s Alzheimer’s Disease Research Center. Contributors include Nicolette Calcavecchia, Dalia Elsaid, Marie Ingegneri, Jason Karlawish, Emily Largent, and Meg McCarthy.